BIOCRYST PHARMACEUTICALS, INC. Payment for Debt Extinguishment or Debt Prepayment Cost
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2025-12-31 was $6.08M.
- BIOCRYST PHARMACEUTICALS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2025-09-30 was $1.55M.
- BIOCRYST PHARMACEUTICALS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2024-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2024-09-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2025 was $9.89M.
- BIOCRYST PHARMACEUTICALS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $21.26M.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.64M derived: sum of 2 quarters · filed 2026-02-26 | $9.89M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.80M 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | $2.25M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $21.26M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |